Genmab Financial Statements From 2010 to 2024
| GMAB Stock | DKK 1,511 23.00 1.55% |
Check Genmab AS financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Genmab AS's main balance sheet or income statement drivers, such as , as well as many indicators such as . Genmab financial statements analysis is a perfect complement when working with Genmab AS Valuation or Volatility modules.
Genmab |
Genmab AS Company Profit Margin Analysis
Genmab AS's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Genmab AS Profit Margin | 0.47 % |
Most of Genmab AS's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genmab AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Genmab AS has a Profit Margin of 0.4717%. This is 104.21% lower than that of the Healthcare sector and 102.05% lower than that of the Biotechnology industry. The profit margin for all Denmark stocks is 137.14% lower than that of the firm.
Genmab AS Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genmab AS's current stock value. Our valuation model uses many indicators to compare Genmab AS value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genmab AS competition to find correlations between indicators driving Genmab AS's intrinsic value. More Info.Genmab AS is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.44 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Genmab AS is roughly 2.29 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Genmab AS by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Genmab AS's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Genmab AS Financial Statements
Genmab AS investors utilize fundamental indicators, such as revenue or net income, to predict how Genmab Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on Copenhagen Stock Exchange in Denmark.
Pair Trading with Genmab AS
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Genmab AS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genmab AS will appreciate offsetting losses from the drop in the long position's value.Moving together with Genmab Stock
| 0.93 | NOVO-B | Novo Nordisk AS | PairCorr |
| 0.8 | ALK-B | ALK Abell AS | PairCorr |
| 0.87 | BAVA | Bavarian Nordic | PairCorr |
| 0.74 | ZEAL | Zealand Pharma AS | PairCorr |
Moving against Genmab Stock
| 0.86 | DSV | DSV Panalpina AS | PairCorr |
| 0.85 | FLS | FLSmidth | PairCorr |
| 0.47 | ISS | ISS AS | PairCorr |
| 0.43 | ORPHA | Orphazyme AS | PairCorr |
The ability to find closely correlated positions to Genmab AS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genmab AS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genmab AS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genmab AS to buy it.
The correlation of Genmab AS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genmab AS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genmab AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genmab AS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Genmab Stock
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out the analysis of Genmab AS Correlation against competitors. To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..